Loading clinical trials...
Loading clinical trials...
Phase II Study of Safety & Efficacy of Deferasirox Given for 1 Year in Patients With Chronic Anemias and Transfusional Hemosiderosis Unable to be Treated With Deferoxamine
Conditions
Interventions
Deferasirox
Locations
6
United States
Children's Hospital Oakland
Oakland, California, United States
Stanford Hospital
Stanford, California, United States
Northwest Medical Specialists
Arlington Heights, Illinois, United States
Children's Hospital Boston
Boston, Massachusetts, United States
Weill Medical College of Cornell University
New York, New York, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Start Date
May 1, 2003
Primary Completion Date
November 1, 2004
Last Updated
August 22, 2017
NCT07270978
NCT05292664
NCT06499285
NCT04953910
NCT04953897
NCT05350748
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions